Avelas Biosciences raises $7.4M for cancer visualization tech; FDA clears new test for acute renal failure;

> Avelas Biosciences said it has closed on the second tranche of its Series B financing, raising a total of $7.4 million to advance clinical development of real-time cancer visualization diagnostic technology. Release

> Through June, Health Diagnostic Laboratory in Virginia paid doctors who sent it patients' blood for cardiac biomarker testing, and now the strategy is under regulatory scrutiny. Story (sub. req.)

> Abbott ($ABT) Laboratories reported positive study results for a new diagnostic that targets blood-related infections and is set to receive a CE mark in the coming months. Story

> Biocept ($BIOC), a molecular diagnostics company focused on cancer, said it has strengthened its patent position in Europe regarding the capture of circulating tumor cells to aid in a diagnosis. Release

> The FDA has cleared a new diagnostic test for acute renal failure. Story

> DiabetOmics said it is rolling out a new point-of-care test designed to detect, assess and monitor preeclampsia in its early stages. Release

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.